| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8773833 | Kidney International Reports | 2018 | 8 Pages |
Abstract
NPT-IIb inhibition with ASP3325 was not effective in reducing serum phosphate levels in ESRD patients. The relevance of NPT-IIb in humans and feasibility of oral NPT-IIb inhibitors for treatment of hyperphosphatemia in ESRD remain uncertain.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Tobias E. Larsson, Chisato Kameoka, Ikumi Nakajo, Yuta Taniuchi, Satoshi Yoshida, Tadao Akizawa, Ronald A. Smulders,